Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
platelet-rich plasma + platelet lysate + platelet-poor plasma
- Development stage
- Unknown
- Lead developer
- Regenexx
- Modality
- Cell Therapies
- Administration
- Percutaneous, Intralesional
01
Overview
This autologous combination therapy consists of platelet-rich plasma (PRP), platelet lysate (PL), and platelet-poor plasma (PPP), developed by Regenexx for the treatment of musculoskeletal conditions, specifically degenerative disc disease. The therapy is designed to leverage the regenerative potential of platelets by providing both a sustained release of growth factors from intact platelets (PRP) and an immediate bolus of growth factors from lysed platelets (PL). Platelet-poor plasma (PPP) serves as a protein-rich scaffold and carrier. The combination is typically administered via percutaneous injection into the functional spinal unit, including the intervertebral disc, facet joints, and supporting ligaments, to stimulate tissue repair, modulate inflammation, and reduce pain in patients with chronic spinal degeneration.
- Brand names
- Regenexx-PRPRegenexx-PLRegenexx-PPP
- Other names
- Regenexx Platelet ProcedureAutologous Platelet-Based TherapyRegenexx-PLRegenexx-PRPRegenexx-PPP
Beyond the preview
Go deeper on platelet-rich plasma + platelet lysate + platelet-poor plasma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on platelet-rich plasma + platelet lysate + platelet-poor plasma.